成人患者利奈唑胺群体药代动力学模型的外部验证

房秋 ,  蒋双妙 ,  王晶 ,  罗雪梅 ,  金路 ,  朱怀军

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1363 -1376.

PDF (2627KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1363 -1376. DOI: 10.12092/j.issn.1009-2501.2026.10.007

成人患者利奈唑胺群体药代动力学模型的外部验证

作者信息 +

External validation of population pharmacokinetic models for linezolid in adult patients

Author information +
文章历史 +
PDF (2689K)

摘要

目的: 评估已发表利奈唑胺群体药代动力学模型的预测性能,探索模型的适用性与局限性。方法: 系统检索 PubMed、中国知网等数据库(建库至 2025 年 6 月),提取模型信息;收集南京鼓楼医院 111 例成人感染患者的 223 个稳态血药浓度数据,通过拟合优度、预测误差检验及可视化预测检验进行外部验证。结果: 本研究共纳入 25 个利奈唑胺群体药代动力学模型,验证显示:群体预测表现欠佳,最优模型 R2 仅 0.28,预测误差在±30%(F30)范围内均低于 35%,所有模型均未达到既定标准;个体预测能力较好,最优模型 R2 达 0.92,IF30 值最高 82.11%,大部分模型展现出良好的预测能力;亚组分析提示,特定临床环境可改善群体预测,高精度个体预测模型稳定性强。结论: 现有的利奈唑胺群体药代动力学模型在本中心患者中预测误差大、外推能力有限,临床适用性不足;个体预测有助于提高模型预测的准确性。未来需纳入更多协变量、扩大特殊人群样本,通过前瞻性研究增强模型泛化能力。

Abstract

AIM: To evaluate the predictive performance of published population pharmacokinetic models for linezolid and explore their applicability and limitations. METHODS: A systematic search was conducted in databases such as PubMed and CNKI (up to June 2025), and model information was extracted. Steady-state blood concentration data from 223 samples of 111 adult infected patients at Nanjing Drum Tower Hospital were collected for external validation using goodness-of-fit tests, prediction error tests, and visual predictive checks. RESULTS: A total of 25 population pharmacokinetic models for linezolid were included in this study. Validation results showed that the population prediction performance was suboptimal, with the best model having an R2 of only 0.28. The prediction error within the ±30% range (F30) was below 35%, and none of the models met the established standards. However, individual prediction capability was relatively good, with the best model achieving an R2 of 0.92 and an IF30 value as high as 82.11%, indicating that most models demonstrated good prediction ability. Subgroup analysis suggested that specific clinical environments could improve population predictions, and high-precision individual prediction models showed strong stability. CONCLUSION: The existing population pharmacokinetic models for linezolid exhibit large prediction errors and limited extrapolation ability in patients at this center, with insufficient clinical applicability. Individual predictions can help improve model accuracy. Future research should incorporate more covariates, expand the sample size of special populations, and enhance model generalizability through prospective studies.

关键词

利奈唑胺 / 群体药代动力学模型 / 外部验证 / 治疗药物监测

Key words

linezolid / population pharmacokinetic models / external validation / therapeutic drug monitoring

引用本文

引用格式 ▾
房秋,蒋双妙,王晶,罗雪梅,金路,朱怀军. 成人患者利奈唑胺群体药代动力学模型的外部验证[J]. 中国临床药理学与治疗学, 2026, 31(10): 1363-1376 DOI:10.12092/j.issn.1009-2501.2026.10.007

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Clemett D, Markham A. Linezolid[J].Drugs, 2000, 59(4): 815-27; discussion 28.

[2]

邢贞建, 李祥, 江慧贤, 等. 应用蒙特卡洛模拟评价中国成人耐多药结核患者利奈唑胺给药方案[J].实用医学杂志, 2020, 36(16): 2216-2219.

[3]

Zhang C, Huang J, Yang P, et al.[Consensus on linezolid in the treatment of tuberculosis(2022 update)][J].Zhonghua Jie He He Hu Xi Za Zhi, 2022, 45: 10: 988-995.

[4]

Beringer P, Nguyen M, Hoem N, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings[J].Antimicrob Agents Chemother, 2005, 49(9): 3676-3681.

[5]

Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability[J].Biopharm Drug Dispos, 2001, 22(3): 91-97.

[6]

Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid[J].Front Public Health, 2022, 10: 967311.

[7]

Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients[J].J Antimicrob Chemother, 2012, 67(8): 2034-2042.

[8]

Sheiner LB, Rosenberg B, Marathe VV.Estimation of population characteristics of pharmacokinetic parameters from routine clinical data[J].J Pharmacokinet Biopharm, 1977, 5(5): 445-79.

[9]

Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'[J].Kidney Int, 2013, 84(3): 622-623.

[10]

Cockcroft DW, Gault MH.Prediction of creatinine clearance from serum creatinine[J].Nephron, 1976, 16(1): 31-41.

[11]

Cai X, Li R, Sheng C, et al. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients[J].Eur J Pharm Sci, 2020, 145: 105237.

[12]

Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill[J].J Antimicrob Chemother, 2005, 55(3): 333-340.

[13]

Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthyvolunteers and septic patients[J].Drug Metab Dispos, 2007, 35(10): 1816-1823.

[14]

Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients[J].J Clin Pharmacol, 2009, 49(9): 1071-1078.

[15]

张雷. 利奈唑胺在中国人群的群体药代/药效动力学研究[D].北京: 解放军医学院, 2011.

[16]

Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction[J].J Clin Pharmacol, 2013, 53(9): 967-973.

[17]

Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients[J].Int J Antimicrob Agents, 2014, 44(3): 242-247.

[18]

Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid[J].Antimicrob Agents Chemother, 2014, 58(4): 2334-2343.

[19]

Töpper C, Steinbach CL, Dorn C, et al. Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions[J].Ther Drug Monit, 2016, 38(5): 573-578.

[20]

Tsuji Y, Holford NHG, Kasai H, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients[J].Br J Clin Pharmacol, 2017, 83(8): 1758-1772.

[21]

Ide T, Takesue Y, Ikawa K, et al. Population pharmacokinetics/ pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy[J].Int J Antimicrob Agents, 2018, 51(5): 745-751.

[22]

Xie F, Mantzarlis K, Malliotakis P, et al. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia[J].J Antimicrob Chemother, 2019, 74(3): 667-674.

[23]

Dong H, Xie J, Wang T, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients[J].Int J Antimicrob Agents, 2016, 48(3): 259-264.

[24]

Wang D, Zheng X, Yang Y, et al. Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count[J].Exp Ther Med, 2019, 18(3): 1786-1792.

[25]

Wang X, Wang Y, Yao F, et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically Ill patients: a multicenter, prospective, open-label, observational study[J].Drug Des Devel Ther, 2021, 15: 2129-2141.

[26]

Fang J, Zhang XS, Zhang CH, et al. Model based identification of linezolid exposure-toxicity thresholds in hospitalized patients[J].Front Pharmacol, 2021, 12: 732503.

[27]

Wicha SG, Mair A, Chiriac U, et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients[J].Int J Antimicrob Agents, 2022, 59(5): 106572.

[28]

Wu F, Zhang XS, Dai Y, et al. Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically Ill patients[J].Front Pharmacol, 2022, 13: 844567.

[29]

Bock M, VAN Hasselt JGC, Schwartz F, et al. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis[J].J Antimicrob Chemother, 2023, 78(12): 2840-2848.

[30]

Liu Q, Li S, Xie F.Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis[J].Int J Antimicrob Agents, 2023, 62(4): 106949.

[31]

Bock M, Theut AM, Van Hasselt JGC, et al. Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a POET substudy[J].Clin Infect Dis, 2023, 77(2): 242-251.

[32]

Li Y, Fang Q, Wu Z, et al. Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients[J].Eur J Clin Pharmacol, 2024, 80(9): 1295-1304.

[33]

Xu J, Chen X, Zhang Q, et al. Population pharmacokinetic/pharmacodynamic study of linezolid in hospital-acquired pneumonia patients with renal insufficiency[J].Drug Des Devel Ther, 2024, 18: 5073-5086.

[34]

Milaković D, Kovačević T, Kovačević P, et al. Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-associated acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation-a step toward correct dosing[J].Pharmaceutics, 2024, 16(2): 418.

[35]

Maha A, Ali M, Bilal H, et al. Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies[J].Pak J Pharm Sci, 2025, 38(1): 291-298.

[36]

Qin Y, Jiao Z, Ye YR, et al. External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients[J].J Glob Antimicrob Resist, 2023, 35: 347-353.

[37]

Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction[J].Antimicrob Agents Chemother, 2003, 47(9): 2775-2780.

[38]

林忠, 谢群莉, 戴淑萍, 等. 中国成年患者利奈唑胺治疗群体药动学研究[J].中国临床药理学与治疗学, 2020, 25(9): 992-999.

[39]

Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism[J].J Clin Pharmacol, 2011, 51(2): 229-236.

[40]

Hashimoto S, Honda K, Fujita K, et al. Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies[J].J Pharm Health Care Sci, 2018, 4: 27.

[41]

Heffernan AJ, Mohd Sazlly Lim S, Lipman J, et al. A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients[J].Anaesth Crit Care Pain Med, 2021, 40(6): 100970.

[42]

Mahmood I, Pettinato M.Impact of intrinsic and extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted?[J].Antibodies (Basel), 2021, 11(1): 2.

[43]

肖莹, 张弋, 李淑娟, 等. 利奈唑胺在重症感染患者中的药动学[J].中国医院药学杂志, 2016, 36(7): 535-539.

[44]

Figuera-Figuera A, Navarro J, Sabaté S, et al. SeDeM as a tool to validate drug substance manufacturing processes and assess scalability and suitability for direct compression: supplier screening[J].Pharmaceutics, 2023, 15(8): 2034.

[45]

Alihodzic D, Broeker A, Baehr M, et al. Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing[J].Front Pharmacol, 2020, 11: 172.

[46]

Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings[J].Br J Clin Pharmacol, 2013, 75(4): 1068-1080.

基金资助

江苏省青年医学人才资助项目(QNRC2016013)

江苏省 333 高层次人才培养计划([2024]3-2409)

南京大学中国医院改革发展研究院课题项目(NDYGN2023027)

AI Summary AI Mindmap
PDF (2627KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉